Specialty Pharmacy Videos

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.
Julianne Orr, PharmD, from Indiana University Health Simon Cancer Center, discusses the pharmacist's role in managing adherence to oral treatment regimens for patients with cancer.
Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.
A look at last week's top stories in the world of pharmacy.
John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses how data aggregators work with pharmacies and manufacturers to boost patient support services.
Luis Torres, MBA, vice president, Managed Care, BioPlus Specialty Pharmacy, discusses the importance of co-pay assistance programs for costly specialty drugs.
Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses how data can translate to improvements in patient care.

Peer Exchange

PEER EXCHANGE > Optimal Utilization of Oral Oncolytics
Peter L. Salgo, MD; Carl T. Henningson, MD; Steven L. D'Amato, RPh, BSPharm; Noa Biran, MD; and Arturo Loaiza-Bonilla, MD, MSEd, FACP, conclude the panel discussion by reviewing future trends in using oral oncolytics, including accessibility and combination therapy.
PEER EXCHANGE > Optimal Utilization of Oral Oncolytics
Peter L. Salgo, MD; Noa Biran, MD; Carl T. Henningson, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP; and Steven L. D'Amato, RPh, BSPharm, outline specific oral oncolytics, including ixazomib for multiple myeloma and regorafenib for gastrointestinal malignancies.
PEER EXCHANGE > Optimal Utilization of Oral Oncolytics
Peter L. Salgo, MD; Noa Biran, MD; Carl T. Henningson, MD; Steven L. D'Amato, RPh, BSPharm; and Arturo Loaiza-Bonilla, MD, MSEd, FACP, explore the different factors affecting reimbursement of oncolytics, including the cost versus benefit.
PEER EXCHANGE > Optimal Utilization of Oral Oncolytics
Peter L. Salgo, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP; Carl T. Henningson, MD; Steven L. D'Amato, RPh, BSPharm; and Noa Biran, MD, discuss the nuances of oral parity laws for oncolytics and how they affect treatment.

Insights

INSIGHTS > Sequencing of Therapy for Rheumatoid Arthritis
Stanley B. Cohen, MD, discusses the future treatment options for rheumatoid arthritis.
INSIGHTS > Sequencing of Therapy for Rheumatoid Arthritis
Stanley B. Cohen, MD, reviews the methodology, results, and clinical importance of the TEAR trial for rheumatoid arthritis.
INSIGHTS > Sequencing of Therapy for Rheumatoid Arthritis
Stanley B. Cohen, MD, describes the use of biologics to treat rheumatoid arthritis.
INSIGHTS > Sequencing of Therapy for Rheumatoid Arthritis
Stanley B. Cohen, MD, details the roles of both oral and subcutaneous methotrexate in the treatment of rheumatoid arthritis.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$